分享
分销 收藏 举报 申诉 / 39
播放页_导航下方通栏广告

类型肺癌筛查对新发结节的研究.pptx

  • 上传人:精***
  • 文档编号:2046024
  • 上传时间:2024-05-14
  • 格式:PPTX
  • 页数:39
  • 大小:808KB
  • 下载积分:12 金币
  • 播放页_非在线预览资源立即下载上方广告
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    肺癌 查对 结节 研究
    资源描述:
    Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT:analysis of data from the randomised,controlled NELSON trial2of39l Lung cancer is a leading cause of death worldwide.l US guidelines now recommend lung cancer screening with low-dose CT for high-risk individuals.l So far,most research has focused on lung nodules detected during baseline screening.Introduction3of39Introductionl Reports of new nodules after baseline screening have been scarce and are inconsistent because of differences in definitions used.l Because these nodules developed within a short time-interval,Lung cancers found in incidence screening rounds tend to be more aggressive than those detected at baseline.4of39l Up to now,no study has focused on new solid nodules found during lung cancer screening.l We aimed to identify the occurrence of new solid nodules and their probability of being lung cancer at incidence screening rounds in the Dutch-Belgian Randomized Lung Cancer Screening Trial(NELSON).Introduction5of39Dutch Belgian randomised lung cancer screening trial(NELSON)Overall trial start date16/08/2003Overall trial end date31/12/20156of39l Organisation:Erasmus Medical Centre(Netherlands)l Participating centres:University Medical Centre Groningen,University Medical Centre Utrecht,Kennemer Gasthuis Haarlem(the Netherlands),and University Hospital Leuven(Belgium).Dutch Belgian randomised lung cancer screening trial(NELSON)7of39Dutch Belgian randomised lung cancer screening trial(NELSON)studyaims:1.Toinvestigatewhetherscreeninginahigh-riskpopulationleadstoareductioninlungcancerdeathsofatleast25%;2.Toestimatetheimpactoflungcancerscreeningonhealth-relatedqualityoflifeandsmokingcessation3.Toestimatecost-effectivenessoflungcancerscreeningforsubgroups.8of39lParticipant inclusion criteria1.Bornbetween1928and1956(50-75years)2.Smoked:2.1.Morethan15cigarettesperdayformorethan25years,or2.2.Morethan10cigarettesperdayformorethan30years3.Currentorformersmokerswhoquitsmokinglessthanorequalto10yearsagol Participant exclusion criteria1.Moderateorbadself-reportedhealthwhowereunabletoclimbtwoflightsofstairs2.Bodyweightgreaterthanorequalto140kg3.Currentorpastrenalcancer,melanomaorbreastcancer4.Lungcancer,diagnosedlessthanfiveyearsagoorgreaterthanorequaltofiveyearsbutstillundertreatment5.HadachestCTexaminationlessthanoneyearDutch Belgian randomised lung cancer screening trial(NELSON)9of39lIntervention1.Screenarm:1.1.16-detectormulti-slicecomputedtomographyofthechestinyearone,twoandfourofthestudy1.2.Pulmonaryfunctiontest1.3.Bloodsampling1.4.Questionnaires1.5.Smokingcessationadviceforcurrentsmokers2.Controlarm:Smokingcessationadviceforcurrentsmokers.Dutch Belgian randomised lung cancer screening trial(NELSON)Methods-Study design and participants10 of39Intheongoing,multicentre,randomisedcontrolledNELSONtrial,betweenDec23,2003,andJuly6,2006.15822participantswereenrolledandrandomlyassignedtoreceiveeitherscreeningwithlow-doseCT(n=7915)ornoscreening(n=7907).7557individualsunderwentbaseline;7295participantsunderwentsecondandthirdscreeningrounds.Methods-Study design and participants11 of39Thesecondscreeningroundtookplace1yearafterthebaselinescan(annualscreen).Thethirdscreeningroundtookplace2yearsafterthesecondscreeningscan(biannualscreen).Resultsofthefourthscreeninground,done55yearsafterbaseline(25yearscreeninginterval).Methods-Study design and participants12 of39Weincludedallparticipantswithsolidnon-calcifiednodules,registeredbytheNELSONradiologistsasneworsmallerthan15mm3(studydetectionlimit)atpreviousscreens.Methods-Procedures13 of39Nodulevolumewasgeneratedsemiautomaticallybysoftware.Thesemiautomatedvolumetricsoftware(LungCARE,versionSomaris/5VA70C-W,SiemensMedicalSolutions,Forchheim,Germany).Onthebasisofthethree-dimensionalnodulevolume,thissoftwarealsosimulatedlongestandperpendicularnodulediameterintheaxialplane.Methods-Procedures14 of39ForsubsequentCTscans,noduleswereindividuallymatchedonpreviousscansbythesoftwaresmatchingalgorithm(dependingonconsistency,size,andlocation),andvisuallycheckedbytheradiologists.Methods-Procedures15 of39Atfirstdetection,solidnoduleswereassessedbasedonvolume.Becausenewnoduleswereconsideredfast-growing,theirfollow-upstrategydifferedfrombaselinenodules.Newnodulesmeasuring1550mm3withoutbenigncharacteristicswereconsideredindeterminate(follow-uplow-doseCTafter1year),newnodulesmeasuring50500mm3werealsoconsideredindeterminate(follow-uplow-doseCTwithin68weeks),andnewnodulesmeasuring500mm3ormorewereconsideredpositive(immediatereferraltopulmonologist).Methods-Procedures16 of39lAfterinitialdetection,subsequentevaluationofanodulewasbasedongrowthandvolumedoublingtime.lWecalculatedthemaximumvolumedoublingtimefornoduleswithanestimatedpercentagevolumechangeof25%ormore.17 of39Methods-ProceduresIn theory,the actual volume doubling time in the examined time interval might have been faster,but not slower,than the calculated maximum time.Methods-Procedures18 of39lFornoduleseventuallydiagnosedascancer,wesupplementeddatawithcancer-specificinformationobtainedatdiagnosis,suchashistologyandstage.lMalignancy was based on histology,and benignity was based on histology or stable size for at least 2 years.Methods-Statistical analysis19 of39NormalitytestingforcontinuousvariableswasdonewiththeKolmogorovSmirnovtest.ContinuousvariableswereanalysedwiththeMannWhitneyUtestandarepresentedasmediansandIQRs.WeusedFishersexacttesttoanalysenominalvariables.Methods-Statistical analysis20 of39Receiveroperatingcharacteristic(ROC)analysiswasdonefornodulevolumewitheventuallungcancerdiagnosisastheoutcometoevaluatetheirperformanceaspredictorsoflungcancerandtoestimatecutoffvalues.Wederivedcutoffvalueswithapredefinedoverallsensitivityof95%.Methods-Statistical analysis21 of39Wedevelopedariskpredictionmodeltoassesswhethertheestablishedrelationbetweenvolumeofanewsolidnoduleandlungcancerdiagnosisremainedsignificantindependentofotherriskfactors(ie,age,sex,pack-years,smokingstatus,timesincepreviousscan,solidnodulecountatbaseline,andnoduleimagingandvolume).Results22 of39Weanalyseddataforparticipantswithatleastonesolidnon-calcifiednoduleatthesecondorthirdscreeninground.Inthetwoincidencescreeningrounds,theNELSONradiologistsregistered1222newsolidnodulesin787(11%)participants.23 of39Table1showscharacteristicsofincludedparticipants.Ahighernumberofpack-yearssmokedandalowernumberofsolidnodulesatbaselinescreeningsignificantlyincreasedtheprobabilityofanewsolidnodulebeinglungcancer.Increasedagewasnotsignificantlyassociatedwithlungcancer.Results24 of39In49(6%)participantswithnewsolidnodules,anewsolidnodulewaslungcancer.Oneparticipantwasdiagnosedwithsynchronousdoubletumoursintwonewnodules.Intotal,50lungcancerswerefound,representing4%ofallnewsolidnodules.25 of39Table 2:New solid new nodules detected during second and third screening rounds(N=1222;1172 benign nodules and 50 lung cancer nodules).Results26 of39Nodule volume had a high discriminatory power(area under the receiver operating curve 0795 95%CI 07280862;p00001).27 of39Results28 of39Nodulessmallerthan27mm3hadalowprobabilityoflungcancer(two05%of417nodules;lungcancerprobability05%95%CI0019),noduleswithavolumeof27mm3upto206mm3hadanintermediateprobability(1731%of542nodules;lungcancerprobability31%1950),andnodulesof206mm3orgreaterhadahighprobability(29169%of172nodules;lungcancerprobability169%120232).Avolumecutoffvalueof27mm3orgreaterhadmorethan95%sensitivityforlungcancer.29 of39Results30 of39Lessthanhalfofscreen-detectedlungcancersinnewsolidnoduleswere500mm3ormoreatfirstnoduledetection.Histologically,mostlungcancerswereadenocarcinomas,squamous-cellcarcinomas,orsmall-celllungcarcinomas.Mostsmall-celllungcarcinomasandsquamous-cellcarcinomashadvolumesgreaterthan500mm3atfirstnoduledetection.However,fewadenocarcinomasinitiallypresentedwithvolumesof500mm3andmore,whereasroughlytwo-fifthsweresmallerthan50mm3atfirstdetection.MostlungcancerswerediagnosedatstageI.Inabouthalfthelungcancercases,participantswerereferredimmediatelyafterfirstnewsolidnoduledetection.Adenocarcinomastendedtobereferredlater.Discussion31 of39Fewstudiesoflungcancerscreeninghavepublisheddetaileddataregardingnewnodulesatincidencescreeningrounds.Furthermore,toourknowledge,thisisthefirsttimenodulevolumecutoffvalueshavebeenestablishedasaguideforfurthermanagementofnewsolidnodules.1.Discussion32 of392.meredetectionofanewsolidnoduleduringincidencescreeningmightcarrythesamelungcancerprobabilityasasuspicioustestresultduringbaselinescreening(6%vs5%;p=025).Discussion33 of393.Atthesetinynodulesizes,growthdetectionbasedontwo-dimensionaldiameterevaluationisunreliable,favouringvolumetry.Discussion34 of39Agewasnotsignificantlyassociatedwithnewnodulelungcancer.Possibleexplanationscouldbethatthenumberofcaseswastoolowtoshowthecorrelation,orperhapsfastnodulegrowthislessassociatedwithage,possiblyevenwithaconverserelation,witholderindividualshavinglessfast-growingnodules.4.Discussion35 of395.Themaximumvolumedoublingtimewassignificantlylowerinnewnodulelungcancersthaninbenignnewsolidnodules.Notably,themedianmaximumvolumedoublingtimeofadenocarcinomas(191daysIQR146348)andsquamous-cellcarcinomas(133days105182)wassimilartopreviouslypublishedvolumedoublingtimeoffast-growingbaselinecancersintheNELSONtrialofthesamehistologicaltype(196daysIQR135250and142days91178,respectively).Discussion36 of396.Comparedwiththeoverallscreeningresultsofthefirstthreerounds,newsolidnodulecancercomprised11(19%)of58cancersfoundinthesecondscreening;and34(44%)of77cancerseveninthethirdscreening;Thus,managementofnewsolidnoduleshasagreatimpactontheoutcomeofalungcancerscreeningprogramme.Discussion37 of397.limitationsWeexcludednodulessmallerthan15mm3,WecannotexcludethepossibilitythattheactualnumberofnewnodulesissomewhathigherthanwereportbasedontheNELSONmanagementsysteminformation.Weincludedonlysolidnodules,withexclusionofpart-solidandpureground-glassnodules.Calculationofamaximumvolumedoublingtimefornewnodulesisanewandnotyetvalidatedapproach,andsoneedsfurtherinvestigation.Ratesofnewsolidnodulesandcancerdifferedbetweentheincidencescreeningrounds.Discussion38 of39Ourstudyshowsthatnewsolidnodulesaredetectedateachscreeningroundin57%ofindividualswhoundergoscreeningforlungcancerwithlow-doseCT.Thesenewnoduleshaveahighprobabilityofmalignancyevenatasmallsize.Thesefindingsshouldbeconsideredinfuturescreeningguidelines.Newsolidnodulesshouldbefollowedupmoreaggressivelythannodulesdetectedatbaselinescreening,forexamplebyusinglowervolumecutoffvalues(27mm3,27mm3to206mm3,206mm3)withasensitivityofmorethan95%.THANK YOU
    展开阅读全文
    提示  咨信网温馨提示:
    1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
    2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,个别因单元格分列造成显示页码不一将协商解决,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
    3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
    4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前可先查看【教您几个在下载文档中可以更好的避免被坑】。
    5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
    6、文档遇到问题,请及时联系平台进行协调解决,联系【微信客服】、【QQ客服】,若有其他问题请点击或扫码反馈【服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【版权申诉】”,意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:0574-28810668;投诉电话:18658249818。

    开通VIP折扣优惠下载文档

    自信AI创作助手
    关于本文
    本文标题:肺癌筛查对新发结节的研究.pptx
    链接地址:https://www.zixin.com.cn/doc/2046024.html
    页脚通栏广告

    Copyright ©2010-2026   All Rights Reserved  宁波自信网络信息技术有限公司 版权所有   |  客服电话:0574-28810668    微信客服:咨信网客服    投诉电话:18658249818   

    违法和不良信息举报邮箱:help@zixin.com.cn    文档合作和网站合作邮箱:fuwu@zixin.com.cn    意见反馈和侵权处理邮箱:1219186828@qq.com   | 证照中心

    12321jubao.png12321网络举报中心 电话:010-12321  jubao.png中国互联网举报中心 电话:12377   gongan.png浙公网安备33021202000488号  icp.png浙ICP备2021020529号-1 浙B2-20240490   


    关注我们 :微信公众号  抖音  微博  LOFTER               

    自信网络  |  ZixinNetwork